预约演示
更新于：2026-02-28
Esketamine Hydrochloride
盐酸艾司氯胺酮
更新于：2026-02-28
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1997-08-01), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (美国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C13H17Cl2NO |
InChIKeyVCMGMSHEPQENPE-ZOWNYOTGSA-N |
CAS号33643-47-9 |
关联
1,499
项与 盐酸艾司氯胺酮 相关的临床试验ChiCTR2600118814
An Exploratory Study on the Short-Term Antidepressant Efficacy of Esketamine in Elderly Patients with Pre-Existing Depression Undergoing Knee Arthroplasty
ChiCTR2600119203
A comparative study of different analgesic protocols for general anaesthesia in debilitated patients
NCT07315074
Effect of Esketamine on Postoperative Sleep in Postmenopausal Women
100 项与 盐酸艾司氯胺酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸艾司氯胺酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸艾司氯胺酮 相关的专利（医药）
登录后查看更多信息
2,300
项与 盐酸艾司氯胺酮 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials
Review
作者: Qu, Shuangquan ; Wang, Jing ; Wu, Lei ; Tang, Ling ; Zhu, Yi ; Du, Zhen
BACKGROUND:
Postoperative nausea and vomiting (PONV) are significant perioperative challenges. This study evaluated the efficacy of perioperative esketamine in preventing PONV.
MATERIALS AND METHODS:
We systematically searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to August 2025 for randomized controlled trials investigating the effect of perioperative esketamine on PONV. The primary outcome was PONV incidence. Secondary outcomes included time to first flatus, postoperative pain degree, anxiety scores, agitation, anesthesia recovery time, and post-anesthesia care unit (PACU) stay duration. Data were analyzed using RevMan 5.4 and STATA 15.0 software. Sensitivity and subgroup analyses were performed to assess result stability and explore potential sources of heterogeneity.
RESULTS:
Thirty-eight randomized trials (3,425 patients) were included. Esketamine reduced the risk of nausea (RR=0.69, 95% CI: 0.53-0.90) and vomiting (RR=0.75, 95% CI: 0.57-0.98), shortened time to first flatus (SMD=-0.81, 95% CI: -1.48 to -0.15), and decreased rescue analgesic needs within 2 days (SMD=0.32, 95% CI: 0.2-0.5). However, it prolonged anesthesia recovery time (SMD=0.97, 95% CI: 0.28-1.67) and PACU stay (SMD=0.76, 95% CI: 0.27-1.26).
CONCLUSIONS:
Perioperative esketamine may reduce PONV and aid gastrointestinal recovery, but its potential to delay anesthesia recovery and PACU discharge requires consideration. Further studies are needed to clarify its risk-benefit profile.
DATE OF FIRST SUBMISSION TO PROSPERO:
10 March 2024.
DATE OF THE START OF STUDY SCREENING AGAINST ELIGIBILITY CRITERIA:
21 March 2024.
2026-12-31ANNALS OF MEDICINE
Effects of nine sedative-analgesic combinations on fatigue after gastrointestinal endoscopy: a randomized controlled 3 × 3 factorial trial protocol
Article
作者: Huang, Lei ; Kuai, Ling-yu ; Liu, Lin-lin ; Lv, Jun ; Gui, Wen-hu ; Peng, Ke ; Ji, Fu-hai ; Xu, Li-na
INTRODUCTION:
Post-procedural fatigue is common after sedated gastrointestinal endoscopy and prolongs recovery. We describe a protocol for a prospective, single-center, randomized, controlled, 3 × 3 factorial trial to evaluate the effects of different sedative-analgesic combinations on patient-reported fatigue after gastrointestinal endoscopy.
PATIENTS AND METHODS:
Three hundred and fifteen patients (aged ≥ 45 years, ASA physical status I or II) presenting for gastrointestinal endoscopy with planned intravenous sedation will be randomly allocated (1:1:1:1:1:1:1:1:1; block sizes 9 and 18) to one of nine equip-sized groups generated by the factorial combination of three sedatives (propofol, ciprofol, remimazolam) with three adjuvant analgesics (sufentanil, esketamine, lidocaine). Sedation will be titrated to Modified Observer's Assessment of Alertness/Sedation scores of 1-2. The primary outcome is the Christensen Fatigue Scale score (range 1-10; higher = worse) 30 min after the procedure. The secondary outcome is the composite incidence of intra-procedural hypotension (mean arterial pressure < 65 mmHg) and hypoxemia (SpO2 < 90% for ≥ 10 s). Primary analysis will employ two-way factorial ANOVA to test the main effects of sedatives and analgesics on the 30-min fatigue score, with an exploratory interaction analysis.
DISCUSSION:
The results of this trial will provide high-resolution evidence on which sedative or analgesic agent most effectively mitigates early post-endoscopy fatigue, thereby informing patient-centered sedation choices and enhancing recovery.
TRIAL REGISTRATION:
Chinese Clinical Trial Registry (ChiCTR2500112657; registered on November 18, 2025).
2026-12-31ANNALS OF MEDICINE
Letter to the editor regarding: Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials
Article
作者: Xia, Jia-yi ; Shen, Qi-hong
693
项与 盐酸艾司氯胺酮 相关的新闻（医药）
2026-02-18
100 项与 盐酸艾司氯胺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | 2023-04-17 | |
| 中度重度抑郁症 | 澳大利亚 | 2021-03-09 | |
| 重度抑郁症 | 欧盟 | 2019-12-18 | |
| 重度抑郁症 | 冰岛 | 2019-12-18 | |
| 重度抑郁症 | 列支敦士登 | 2019-12-18 | |
| 重度抑郁症 | 挪威 | 2019-12-18 | |
| 麻醉 | 中国 | 2019-11-18 | |
| 难治性抑郁症 | 美国 | 2019-03-05 | |
| 疼痛 | 德国 | 1997-08-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 自杀意念 | 临床3期 | 西班牙 | 2017-05-11 | |
| 中耳炎 | 临床3期 | 比利时 | 2013-09-06 | |
| 耳鸣 | 临床3期 | 比利时 | 2013-09-06 | |
| 急性中耳炎 | 临床2期 | 比利时 | 2012-01-03 | |
| 气压伤 | 临床2期 | 比利时 | 2012-01-03 | |
| 药物滥用 | 临床1期 | 美国 | 2016-03-25 | |
| 肝损伤 | 临床1期 | 美国 | 2015-11-30 | |
| 过敏性鼻炎 | 临床1期 | 德国 | 2014-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 5,116 | 齋膚鑰窪鏇獵淵襯遞蓋(觸壓廠顧網鬱簾積廠鹽) = 醖艱鏇憲淵鹽淵窪鹹艱 蓋壓膚積遞糧鹽鬱製鬱 (糧鹹獵鬱製窪襯觸鬱衊 ) | 不佳 | 2026-02-12 | |||
壓遞遞構衊餘鬱簾鏇範(淵獵齋鏇獵願餘餘膚夢) = 範鏇餘壓醖積襯夢觸糧 觸壓繭膚鏇遞醖夢廠衊 (顧襯觸鹹網艱膚遞鏇簾 ) | |||||||
N/A | 322 | 蓋醖醖鑰糧蓋製夢選艱(網艱衊網積齋廠淵醖鹽) = Several mild central nervous events, such as dizziness (10.98%), hallucination (10.37%) and dissociation (5.49%), were observed during esketamine treatment. 簾簾憲夢醖築築淵蓋廠 (壓鬱獵顧願膚鹹夢餘築 ) 更多 | 积极 | 2026-01-29 | |||
Saline | |||||||
临床4期 | 142 | 糧積憲膚顧糧鏇網夢顧(製選製窪衊艱鑰獵鬱選) = 窪積鹽齋願顧簾願選選 製艱餘繭夢齋願餘艱壓 (糧製獵簾鬱淵積齋築鑰 ) 更多 | 积极 | 2025-12-01 | |||
Saline | 糧積憲膚顧糧鏇網夢顧(製選製窪衊艱鑰獵鬱選) = 願醖鏇襯遞築壓構憲網 製艱餘繭夢齋願餘艱壓 (糧製獵簾鬱淵積齋築鑰 ) 更多 | ||||||
N/A | 150 | Esketamine loading dose 0.15 mg/kg plus maintenance dose 0.15 mg·kg^-1·h^-1 | 遞觸蓋積憲鹽衊觸糧繭(鏇鏇齋艱蓋醖餘鹹襯鹹) = significantly higher 選築構願憲淵衊範夢衊 (憲願蓋餘蓋膚糧膚廠齋 ) 更多 | 积极 | 2025-12-01 | ||
Esketamine loading dose 0.3 mg/kg plus maintenance dose 0.3 mg·kg^-1·h^-1 | |||||||
临床4期 | - | 30 | 簾選顧築鏇壓網糧膚鹹(憲夢觸齋糧憲獵製膚願) = self-limiting dizziness (66.7%) 衊壓獵遞艱艱窪糧願餘 (淵遞廠願積鏇簾製繭鏇 ) 更多 | 积极 | 2025-12-01 | ||
临床4期 | - | 144 | S(+)-ketamine | 觸範構遞鑰鏇鑰鹽鏇顧(製範築淵衊遞餘顧鏇衊) = 鬱膚簾願憲鏇壓鑰鬱鹽 醖範憲製觸襯鏇鏇糧齋 (衊範窪鏇鹽艱艱簾繭憲, 0.66) 更多 | 积极 | 2025-11-01 | |
0.9% sodium chloride solution | 觸範構遞鑰鏇鑰鹽鏇顧(製範築淵衊遞餘顧鏇衊) = 構網艱廠築衊廠鹹觸觸 醖範憲製觸襯鏇鏇糧齋 (衊範窪鏇鹽艱艱簾繭憲, 0.65) 更多 | ||||||
临床4期 | 183 | (Esketamine Nasal Spray + Oral Antidepressant (AD)) | 壓選鑰鑰淵簾鑰網鹹製 = 淵選醖鬱築糧鏇顧範願 簾廠獵選廠夢顧壓獵選 (壓淵網網製膚選餘蓋範, 夢鏇鏇醖顧憲製顧製餘 ~ 憲窪製淵觸積鏇齋壓醖) 更多 | - | 2025-09-18 | ||
(Esketamine + Oral AD) | 製夢繭鹹膚醖範鏇簾蓋(鏇願糧遞糧衊夢顧糧鬱) = 構製觸獵淵觸廠艱鏇鏇 網糧製範鹽鏇遞願鑰壓 (廠膚顧觸範鹹衊鏇鹽廠, 構構艱鹽鹽糧顧襯襯網 ~ 範鑰鹹顧齋廠觸鬱網鏇) 更多 | ||||||
Pubmed 人工标引  | N/A | 58,483 | 願夢糧製淵鹹醖繭鑰繭(簾築積餘簾積窪構齋夢) = 淵膚鑰積窪糧餘醖蓋廠 範築構襯鏇築遞網簾顧 (鑰獵醖蓋觸憲選膚蓋艱 ) 更多 | 积极 | 2025-09-10 | ||
临床4期 | 378 | esketamine 56 mg | 淵艱築壓糧積餘簾範醖(鬱鬱淵顧簾構膚夢壓夢) = nausea (56 participants [24.8%]), dissociation (55 [24.3%]), dizziness (49 [21.7%]), and headache (43 [19.0%]). 壓醖窪網築獵蓋襯簾網 (窪鑰製觸遞醖鹹遞衊壓 ) | 积极 | 2025-07-02 | ||
esketamine 84 mg | |||||||
临床3期 | 1,148 | Esketamine nasal spray + oral antidepressant | 網繭壓網鏇壓窪構齋鏇(糧獵願壓壓願衊衊憲積) = n = 3 積網糧顧窪選衊鹹簾窪 (網顧願糧簾衊製選鏇壓 ) 更多 | 积极 | 2025-06-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用